Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.

J Pathol · 2023 · PMC10107453 · PMID 36373784

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a marginal trendno p-value reported

We observed that predominant cell line‐derived xenografts with a good response [treatment/control (T/C) ratio < 0.3] to elimusertib showed elevated nuclear pCHK1 staining levels, and therefore showed a marginal trend towards higher elimusertib sensitivity.

also in 111 other papers

showed a trendno p-value reported

Using an advanced multispectral imaging system in subsequent cell line‐derived xenograft specimens, we showed a trend between nuclear phosphorylated CHK1 (pCHK1) staining and increased sensitivity to the ATR inhibitor elimusertib, indicating the potential value of pCHK1 expression as a predictive biomarker of ATR inhibitor sensitivity. © 2022 The Authors.

also in 15,197 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.